



Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)

David Tougeron, Pierre Michel, Astrid Lièvre, Michel Ducreux, Sébastien Gaujoux, Boris Guiu, Florence Huguet, Thierry Lecomte, Côme Lepage, Christophe Louvet, et al.

► To cite this version:

David Tougeron, Pierre Michel, Astrid Lièvre, Michel Ducreux, Sébastien Gaujoux, et al.. Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). Digestive and Liver Disease, 2021, 53 (3), pp.306-308. 10.1016/j.dld.2020.11.029 . hal-03102287

HAL Id: hal-03102287

<https://hal.science/hal-03102287>

Submitted on 4 Feb 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Letter to the editor

Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR).

D. Tougeron (1), P. Michel (2), A. Lièvre (3), M. Ducreux (4), S. Gaujoux (5), B. Guiu (6), F. Huguet (7), T. Lecomte (8), C. Lepage (9), C. Louvet (10), L. Maggiori (11), P. Mariani (12), T. Aparicio (13), O. Bouché (14) on behalf of the Thésaurus National de Cancérologie Digestive (TNCD), Société Nationale Française de Gastroentérologie (SNFGE), Fédération Francophone de Cancérologie Digestive (FFCD), Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR), Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER), Société Française de Chirurgie Digestive (SFCD), Société Française d'Endoscopie Digestive (SFED), Société Française de Radiothérapie Oncologique (SFRO), Association de Chirurgie Hépato-Bilio-Pancréatique et Transplantation (ACHBT), and Société Française de Radiologie (SFR).

- (1) Gastroenterology and Hepatology department, Poitiers University Hospital; University of Poitiers, Poitiers, France.
- (2) Normandie Univ, UNIROUEN, Inserm U1245, IRON group; Rouen University Hospital, Gastroenterology and Hepatology department, Rouen, France.
- (3) Rennes 1 University, Rennes, France; Gastroenterology department, Pontchaillou University Hospital, Rennes, France; INSERM UMR 1242, COSS "Chemistry,

- Oncogenesis, Stress Signaling", Rennes, France; Centre Régional de Coordination des
Dépistage des Cancers, antenne d'Ille-et-Vilaine (Adeci 35), France.
- (4) Digestive Oncology department, Gustave Roussy Institut, Villejuif; Paris-Saclay
University, France.
- (5) Digestive Surgical department, Pitié-Salpêtrière University Hospital, Paris, France.
- (6) Radiology department, Montpellier University Hospital, Montpellier, France.
- (7) Radiotherapy department, Tenon University Hospital, Institut Universitaire de
Canécrologie, APHP; Sorbonne University, Paris, France.
- (8) Gastroenterology, Digestive Oncology and Hepatology department, Tours University
Hospital; UMR INSERM 1069 N2C, Tours University, Tours, France.
- (9) Gastroenterology and Hepatology department, Le Bocage University Hospital;
EPICAD INSERM LNC-UMR 1231, Bourgogne and Franche Comté University,
Dijon, France.
- (10) Medical Oncology department, Mutualiste Montsouris Institut, Paris, France.
- (11) Digestive Surgery department, St Louis University Hospital, Paris, France.
- (12) Oncologic Digestive Surgery department, Curie Institut, Paris, France.
- (13) Gastroenterology and Digestive Oncology department, Saint Louis Hospital, APHP ;
Nord, Université de Paris, Paris.
- (14) Digestive Oncology department, Reims University Hospital, Reims, France.

Corresponding author

Pr David Tougeron, Gastroenterology and Hepatology department, Poitiers University
Hospital, 2 rue de la Milétrie, 86000, Poitiers, France

E-mail address: david.tougeron@chu-poitiers.fr

Tel: +33-5-49-44-37-51; Fax: +33-5-49-44-38-35

Word count: 995

Dear Editor,

The European second wave of the COrona VIRus Disease 2019 (COVID-19) pandemic requires us to think again our practice of digestive oncology. These proposals are based on a recent literature review, the first national digestive oncology guidelines group (TNCD) recommendations (1) and the experience of the first wave of the COVID-19 pandemic.

The risk of death from COVID-19 in patients treated for cancer was overestimated in the first studies (1). In large European cohorts and a recent meta-analysis, death and severity of COVID-19 were mostly due to patients' characteristics with low impact of cancer treatments (2-4). In the French GCO-002 CACOV19 cohort (n=1289), independent factors associated with death, in multivariate analysis, were male gender, ECOG performance status ≥ 2 and the updated Charlson comorbidity index (ICCa) (2).

The impact of the reorganization of healthcare systems during the first wave of the COVID-19 pandemic was major on cancer care pathways (5-8). The French ONCOCARE-COV study confirmed a reduction in terms of colon cancer screening (-86%), histopathological (-48%) and biomolecular (somatic and germinal) (-69%) analyses, oncology announcement consultations (-54%), oncogeriatric evaluations (-86%) and new patients files discussed in multidisciplinary tumor board meeting (MTBM) (-39%) (5). The decrease in cancer treatment was also significant concerning surgery (-30%) and to a lesser extent for radiotherapy (-16%) and chemotherapy (-9%); all clinical research trials were stopped for 3 months (5). The prognostic impact of delay in diagnosis and treatment is not yet known, but population-based modeling analyses are worrying (9).

Thus, due to the second wave of the COVID-19 pandemic, it seems essential to maintain cancer diagnosis and treatments if possible while preserving access to specialized tertiary cancer care and, when necessary, access to intensive care units to ensure continuity of care.

All recommendations were proposed by the steering committee (COPIL) of the TNCD on November 3rd, 2020 and based on an expert agreement in the absence of sufficient data from the literature. These proposals must be interpreted according to the intensity of the epidemic and its impact on the organization of healthcare structures. The present letter is a summary of the French intergroup guidelines available on the TNCD website (www.tncd.org).

1/ Patients care

- Cancer screening and diagnostic procedures (imaging and endoscopy) should be continued since the cumulative diagnostic and therapeutic delays could have major consequences.
- Patients, as well as the whole population, must be reminded of the need not to forego care, screening and prevention actions when these are offered by health professionals and care establishments.
- It is necessary to preserve, as much as possible, the diagnosis announcement procedure with the oncology nurses. They ensure a good understanding of the treatments and their potential side effects, the follow-up, the effectiveness of the surveillance, the continuity of home care, and the good management/compliance of oral drugs. They can also contribute to reschedule postponed medical cares.
- Supportive and palliative cares should be preserved (pain management, diet counseling, psychological support, adapted physical activity, etc.).
- It is recommended to vaccinate patients against Influenza and *Streptococcus pneumoniae*.
- Except before surgery, there is no indication to screen for COVID-19 in asymptomatic patients (especially before chemotherapy courses or consultations).

2/ Proposed adaptations of medical treatments

- As far as possible, no therapeutic modification that could lead to a loss of chance (unplanned therapeutic reduction) and/or an increased toxicity (replacement of 5FU to unplanned oral capecitabine) should be carried out.
- If therapeutic delays are necessary, they should only concern the patients at risk of a severe form of COVID-19: older patients and/or with poor general condition and/or with co-morbidities (heart disease, diabetes, chronic pulmonary disease, chronic renal failure, cirrhosis and/or body mass index > 40 kg/m²).
- If necessary, therapeutic adjustments may be considered if they do not constitute a loss of chance for patients according to the recommendations of the first COVID-19 TNCD (1).
- Therapeutic adjustments must be recorded and/or discussed during a MTBM.
- In case of COVID-19 infection, wait at least 14 days, and 48 hours without cough and fever, and if possible 3 weeks, before resuming treatment with chemotherapy, tyrosine kinase inhibitors or immunotherapy (7 days is enough for asymptomatic form).

3/ Proposed adaptations of surgical treatments

- Surgical units and non-COVID-19 postoperative critical cares should be preserved.
- If possible, no oncologic surgery should be postponed.
- If necessary, a postponement of surgery can only be considered if it is for a short duration and using a validated neo-adjuvant treatment recorded and/or discussed during a MTBM and according to the recommendations of the first COVID-19 TNCD (1).
- If postponement of surgery is not possible but necessary due to the local situation, a transfer to another regional hospital should be discussed.

4/ Proposed adaptations of interventional radiology and radiotherapy

- If possible, no interventional radiology or radiotherapy should be postponed.
- For the neoadjuvant treatment of rectal cancers, if the local context does not allow standard chemoradiotherapy, short course radiotherapy (5x5 Grays) followed by chemotherapy (9 courses of FOLFOX) is a new alternative validated by the RAPIDO trial (10).
- Radiation therapy should not be interrupted in case of COVID-19 infection except for patients with a severe form.

5/ Proposed adaptations for follow-up

- If possible, oncology announcement consultations should be done face-to-face, given the potential loss of chance for patients to perform these consultations by phone or video consultation.
- Follow-up consultations can be carried out by phone or video consultation if possible.
- Postponement of imaging examinations and follow-up consultations can only be considered for patients at low risk of recurrence.

6/ Proposed adaptation of cancer research

- If possible, patient inclusions in clinical trials should be continued, as well as monitoring of patients in clinical trials.
- Cancer research must also be continued.

In conclusion, France's second wave of COVID-19 could be worse than the first. Adaptation of strategies in cancer care is necessary but postponement of cancer screening, diagnosis and treatment with late diagnostic and therapeutic delay have major consequences. Indeed, it

seems important to ensure continuity of cancer care as much as possible. Recommendations proposed in this letter were based on a multidisciplinary overview and experts' agreement and should be adapted according to the situation in each hospital.

Declaration of Competing Interest

None of the other authors have any conflict of interest to declare.

Financial Disclosure

None

Acknowledgements

We thank the French cancer cooperative groups (GCO). We also Sheik Emambux for reviewing our original English-language manuscript.

References

1. Di Fiore F, Bouché O, Lepage C, et al; Thésaurus National de Cancérologie Digestive (TNCD); Société Nationale Française de Gastroentérologie (SNFGE); Fédération Francophone de Cancérologie Digestive (FFCD); Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Société Française de Chirurgie Digestive (SFCD); Société Française d'Endoscopie Digestive (SFED); Société Française de Radiothérapie Oncologique (SFRO) and Société Française de Radiologie (SFR); Association Chirurgie Hepato-Biliaire et Transplantation (ACHBT). COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). *Dig Liver Dis* 2020;52:597-603.
2. Lièvre A, Turpin A, Ray-Coquard I, et al. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOV-19). *Eur J Cancer* 2020;141:62-81.
3. Zhang H, Han H, He T, et al. Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis. *J Natl Cancer Inst.* 2020 Nov 2:djaa168.
4. Pinato DJ, Zambelli A, Aguilar-Company J, et al. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. *Cancer Discov* 2020:CD-20-0773.
5. Brugel M, Carlier C, Essner C, et al. Dramatic changes in oncology care pathways during the COVID-19 pandemic: The French ONCOCARE-COV study. *Oncologist* 2020 Oct 28.
6. De Vincentiis L, Carr RA, Mariani MP, Ferrara G. Cancer diagnostic rates during the 2020 “lockdown”, due to COVID-19 pandemic, compared with the 2018-2019: an audit study from cellular pathology. *J Clin Pathol* 2020:206833.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
7. Mahase E. Covid-19: Urgent cancer referrals fall by 60%, showing “brutal” impact of pandemic. *BMJ* 2020;369:m2386.
8. Chang EI, Liu JJ. Flattening the curve in oncologic surgery: Impact of Covid-19 on surgery at tertiary care cancer center. *J Surg Oncol* 2020 Jun 2;10.1002.
9. Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. *Lancet Oncol* 2020;21:1023-1034.
10. van der Valk MJM, Marijnen CAM, van Etten B, et al; Collaborative investigators. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial. *Radiother Oncol* 2020;147:75-83.